Pirenzepine is an antimuscarinic agent used to treat peptic ulcers, gastric ulcers, and duodenal ulcers. An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function.
- Mechanism
- Curator reviewed
Pirenzepine is a muscarinic receptor antagonist and binds to the muscarinic acetylcholine receptor. The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins.
- Primary indication
- For the treatment of peptic ulcer, gastric ulcer, and duodenal ulcer.Curator reviewed · 2 structured indications
- Formula / weight
- C19H21N5O2 · 351.4023 g/mol (avg)
- First approval
- Canada, 1984
- Code names
- ACI-91 · L-S519
Resolves to
RMHMFHUVIITRHF-UHFFFAOYSA-NSMILESCN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1What you can answer from here — as of September 23, 2026
Which drugs share a target with Pirenzepine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account